<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166970</url>
  </required_header>
  <id_info>
    <org_study_id>Hilar stenting</org_study_id>
    <nct_id>NCT02166970</nct_id>
  </id_info>
  <brief_title>Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction</brief_title>
  <official_title>Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soon Chun Hyang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Bismuth II-IV hilar cholangiocarcinoma patients with a predicted survival of longer than 3
      months, metallic stent performance is superior to plastic stenting for palliation with
      respect to outcomes and cost-effectiveness. However, the optimal stent type and the extent of
      drainage are issues that remain to be definitively decided. The optimal endoscopic management
      strategy is contentious. The investigators conduct the present study to prospectively in
      multi-centers compare unilateral (single) with bilateral (multiple) deployment in inoperable
      malignant biliary obstructions to clarify the clinical outcomes of these two deployment
      methods using metallic stents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Bismuth II-IV hilar cholangiocarcinoma patients with a predicted survival of longer than 3
      months, metallic stent performance is superior to plastic stenting for palliation with
      respect to outcomes and cost-effectiveness.

      However, the optimal stent type and the extent of drainage are issues that remain to be
      definitively decided. The optimal endoscopic management strategy is contentious.

      The investigators conduct the present study to prospectively in multi-centers compare
      unilateral (single) with bilateral (multiple) deployment in inoperable malignant biliary
      obstructions to clarify the clinical outcomes of these two deployment methods using metallic
      stents.

      First as an unilateral or bilateral stent will be deployed according to criteria.

      In bilateral group, stent-in-stent or side-by-side deployment will be included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Actual">October 30, 2016</completion_date>
  <primary_completion_date type="Actual">February 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reintervention rate when stents occluded</measure>
    <time_frame>2 years</time_frame>
    <description>When the stents occluded after successful single or multiple stent deployment, the outcome measure is assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success of single or multiple stents</measure>
    <time_frame>1 month</time_frame>
    <description>When the bilirubin level decrease more than 50% within one week or 75% within one month.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Klatskin Tumor</condition>
  <arm_group>
    <arm_group_label>Single stent deployment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple stent deployment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metallic stent deployment in hilar obstruction</intervention_name>
    <description>Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment</description>
    <arm_group_label>Single stent deployment</arm_group_label>
    <arm_group_label>Multiple stent deployment</arm_group_label>
    <other_name>Single stent insertion</other_name>
    <other_name>Multiple stent insertion using stent-in-stent method</other_name>
    <other_name>Multiple stent insertion using side-by-side method</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  inoperable hilar malignancy

        Exclusion Criteria:

          -  age under 18 years

          -  uncontrolled coagulopathy

          -  inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Hoon Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SoonChunHyang University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tae Hoon Lee</name>
      <address>
        <city>Cheonan</city>
        <zip>330721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soon Chun Hyang University</investigator_affiliation>
    <investigator_full_name>Tae Hoon Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hilar tumor</keyword>
  <keyword>Metal stent</keyword>
  <keyword>Single</keyword>
  <keyword>Multiple</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

